Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer

PURPOSE: Resistance to trastuzumab therapy is linked to phosphoinositol 3-kinase (PI3K) pathway activation. One key downstream effector and regulator of this pathway is the mechanistic target of rapamycin (mTOR). In 2011, a phase I/II study evaluated the combination of trastuzumab and everolimus (a...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Cancer Res Clin Oncol
Egile Nagusiak: de Oliveira Taveira, Mateus, Nabavi, Sheida, Wang, Yuker, Tonellato, Peter, Esteva, Francisco J., Cantley, Lewis C., Wulf, Gerburg M.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer Berlin Heidelberg 2017
Gaiak:
Original Article – Clinical Oncology
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5486569/
https://ncbi.nlm.nih.gov/pubmed/28247034
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00432-017-2358-x
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak